{"id":"liraglutide-and-mitiglinide","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide activates GLP-1 receptors on pancreatic beta cells, promoting glucose-dependent insulin secretion and slowing gastric emptying. Mitiglinide acts as a rapid-acting insulin secretagogue by binding to ATP-sensitive potassium channels on beta cells, triggering quick insulin release in response to meals. Together, they provide complementary glucose-lowering effects through different mechanisms.","oneSentence":"This combination uses liraglutide (a GLP-1 receptor agonist) to enhance insulin secretion and improve glycemic control, paired with mitiglinide (a meglitinide) to stimulate rapid insulin release from pancreatic beta cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:24:35.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02503943","phase":"PHASE4","title":"Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital of Third Military Medical University","startDate":"2015-05","conditions":"Type 2 Diabetes, Overweight, Obesity","enrollment":90}],"_emaApprovals":[],"_faersSignals":[{"count":322450,"reaction":"DRUG INEFFECTIVE"},{"count":247356,"reaction":"OFF LABEL USE"},{"count":247198,"reaction":"NAUSEA"},{"count":235266,"reaction":"FATIGUE"},{"count":195881,"reaction":"DIARRHOEA"},{"count":191645,"reaction":"DYSPNOEA"},{"count":184660,"reaction":"HEADACHE"},{"count":178051,"reaction":"PAIN"},{"count":157609,"reaction":"DIZZINESS"},{"count":151415,"reaction":"DEATH"}],"_approvalHistory":[{"date":"20100917","type":"ORIG","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20140103","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20200820","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"19990406","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19810828","type":"ORIG","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20001128","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19880726","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20000403","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20111221","type":"ORIG","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20150902","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20150902","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20120626","type":"ORIG","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20150518","type":"SUPPL","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20150903","type":"SUPPL","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20250620","type":"SUPPL","sponsor":"XIROMED","applicationNumber":"ANDA206120"},{"date":"20170912","type":"ORIG","sponsor":"XIROMED","applicationNumber":"ANDA206120"}],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"\"Liraglutide\" and \"Mitiglinide\"","genericName":"\"Liraglutide\" and \"Mitiglinide\"","companyName":"Third Affiliated Hospital of Third Military Medical University","companyId":"third-affiliated-hospital-of-third-military-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses liraglutide (a GLP-1 receptor agonist) to enhance insulin secretion and improve glycemic control, paired with mitiglinide (a meglitinide) to stimulate rapid insulin release from pancreatic beta cells. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}